Ivermectin use in children below 15 kg: potential benefits for onchocerciasis and scabies elimination programmes
- PMID: 31693749
- DOI: 10.1111/bjd.18685
Ivermectin use in children below 15 kg: potential benefits for onchocerciasis and scabies elimination programmes
Comment on
-
Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study.Br J Dermatol. 2020 Apr;182(4):1003-1006. doi: 10.1111/bjd.18369. Epub 2019 Sep 29. Br J Dermatol. 2020. PMID: 31344258
References
-
- Levy M, Martin L, Bursztejn AC et al. Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study. Br J Dermatol 2020; 182:1003-6.
-
- Colebunders R, Abd-Elfarag G, Carter JY et al. Clinical characteristics of onchocerciasis-associated epilepsy in villages in Maridi County, Republic of South Sudan. Seizure 2018; 62:108-15.
-
- Chesnais CB, Nana-Djeunga HC, Njamnshi AK et al. The temporal relationship between onchocerciasis and epilepsy: a population-based cohort study. Lancet Infect Dis 2018; 18:1278-86.
-
- Newell ED. Effect of mass treatments with ivermectin, with only partial compliance, on prevalence and intensity of O. volvulus infection in adults and in untreated 4 and 5 year-old children in Burundi. Trop Med Int Health 1997; 2:912-16.
-
- Engelman D, Cantey PT, Marks M et al. The public health control of scabies: priorities for research and action. Lancet 2019; 394:81-92.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical